Vertebral Artery Stenosis Clinical Trial
Official title:
Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents
| NCT number | NCT00172458 |
| Other study ID # | 9361700454 |
| Secondary ID | |
| Status | Recruiting |
| Phase | N/A |
| First received | September 12, 2005 |
| Last updated | September 14, 2005 |
Vertebral artery stenosis (VAS) decreases posterior brain perfusion, causing vertebrobasilar
insufficiency (VBI). It is also an important embolic source to the posterior brain. The most
frequently involved location is the proximal part of the vessel, including the ostium.
Various surgical procedures have been described for the treatment of proximal VAS with
symptoms refractory to medical therapy, but all are technically difficult with high
operative mortality and morbidity.
Endovascular intervention has been described as an alternative to surgery. Balloon
angioplasty is limited by elastic recoil and dissection. The restenosis rates reported in
the literature varied, as high as 75 %. Stenting offers salvage following unsuccessful
balloon angioplasty, and primary stenting have been shown to be safe and effective with
lower restenosis rate. Coronary equipments are ideal for ostial VAS, considering the size of
the artery and location of the lesion. Recently, Albuquerque et al. reports a relative high
restenosis rate in a longer follow-up duration. Restenosis seems to become an important
issue regarding the patients’ quality of life. However, there is no clinical parameter to
predict restenosis of VAS. The purpose of this study is to evaluate the clinical results of
our series of symptomatic ostial VAS treated exclusively with tubular balloon expandable
coronary stents. We sought to identify predictors of restenosis.
This is a clinical observation study. Only chart review and angiographic review will be
performed.
| Status | Recruiting |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | |
| Gender | Both |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: Patients with symptomatic vertebral artery stenosis treated by stenting Exclusion Criteria: |
Observational Model: Defined Population, Time Perspective: Longitudinal
| Country | Name | City | State |
|---|---|---|---|
| Taiwan | National Taiwan University Hospital | Taipei |
| Lead Sponsor | Collaborator |
|---|---|
| National Taiwan University Hospital |
Taiwan,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06186024 -
A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL FOR THE NEW SIZES OF BRIDGE STENTS FOR VERTEBRAL ARTERY STENOSIS: Bridge-MAX
|
N/A | |
| Active, not recruiting |
NCT03999983 -
Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)
|
||
| Recruiting |
NCT03504657 -
Drug-coated Balloon Angioplasty for Patients With Symptomatic Vertebral Artery Stenosis
|
Phase 2 | |
| Completed |
NCT03201432 -
Drug Eluting Stents Versus Bare Metal Stents for Treatment of Symptomatic Extracranial Vertebral Artery Stenosis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05644314 -
Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis
|
N/A | |
| Completed |
NCT03859674 -
Firehorus Rapamycin Target Eluting Vertebral Artery Stent System in Clinical Application
|
N/A | |
| Recruiting |
NCT06301776 -
A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge
|
N/A | |
| Recruiting |
NCT05885932 -
Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis
|
N/A |